out with the keywords "chronic renal disease" OR "chronic kidney disease" OR "clinical characteristics" AND "coronavirus 2019" OR "COVID-19" OR "2019-nCoV" OR "SARS-CoV-2", between 2019 and present time (i.e., March 9, 2020) with no language restrictions applied. The title, abstract and full text of all articles identified that matched the search criteria were assessed, and those reporting the rate of CKD in COVID-19 patients with clinically validated definition of "severe disease" were included in this metaanalysis. The references of all identified studies were also analyzed (forward and backward citation tracking) to identify other potentially eligible articles.
A meta-analysis was performed on retrievable data, including the estimation of the odds ratio (OR) and its 95% confidence interval (95% CI) in patients with or without severe forms of COVID-19. The statistical analysis was performed with MetaXL, software Version 5.3 (EpiGear International Pty Ltd., Sunrise Beach, Australia). The study was carried out in accordance with the Declaration of Helsinki and with the term of local legislation.
Overall, 84 articles could be originally detected based on our electronic and reference search which, after screening by title, abstract and full text, 80 were excluded as not specifically related to COVID-19 (n = 25), were review articles (n = 7), did not provide relevant data (n = 28), were editorials (n = 10), did not include information on severity and/or comorbidities (n = 8), compared patients by mortality but not by severity (n = 1), or compared mild to critical cases (n = 1). Therefore, a final number of four studies could be included in our meta-analysis, including 1389 COVID-19 patients, among which 273 (19.7%) were classified as having severe disease [3] [4] [5] [6] .
The essential characteristics of included studies are summarized in Table 1 , whilst the individual and pooled ORs for CKD predicting severe COVID-19 is shown in Fig. 1 . No study individually found CKD as significant clinical predictor of severe COVID-19. However, when data of individual studies were pooled, a significant association of CKD with severe COVID-19 was observed, with no relevant heterogeneity [OR 3.03 (95% CI 1.09-8.47), I 2 = 0.0%, Cochran's Q, p = 0.84].
Based on a contrite meta-analysis of early and preliminarily available data, CKD seems to be associated with enhanced risk of severe COVID-19 infection. Patients with CKD should hence be advised to take extra precaution to minimize risk exposure to the virus. Physicians should also be engaged in close monitoring of CKD patients with suspected COVID-19, for timely detecting signs of disease progression. Finally, the presence of CKD shall be regarded as an important factor in future risk stratification models for COVID-19. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. 
